Thyroid cancer comprises different clinical and histological entities. Whereas differentiated
(DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary …

Thyroid cancer is the most prevalent endocrine malignancy that comprises mostly indolent
differentiated cancers (DTCs) and less frequently aggressive poorly differentiated (PDTC) or …

Although papillary thyroid cancer (PTC) is curable with excellent survival rate, patients with
dedifferentiated PTC suffer the recurrence or death. As cancer immune escape plays a …

Background The authors report results from the thyroid carcinoma cohort of the multicohort
phase 2 KEYNOTE‐158 study (NCT02628067), which evaluated pembrolizumab …

Immune system plays a key role in cancer prevention as well as in its initiation and
progression. During multistep development of tumors, cells must acquire the capability to …

The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) immune
checkpoint proteins hold promise as diagnostic, prognostic, and therapeutic targets for …

The expression of programmed death-ligand 1 (PD-L1) is an established prerequisite for the
administration of checkpoint inhibitor therapy and is of prognostic value in several cancer …

Programmed cell death ligand 1 (PD‐L1), inducing T cell exhaustion to facilitate immune
escape of tumor cells, is upregulated by interleukin 6 (IL‐6) in T cell lymphoma and ovarian …

Poorly differentiated thyroid carcinoma (PDTC) is an aggressive form of thyroid cancer that
currently has limited effective treatment options. Immune checkpoint inhibitors (ICIs) have …

The new immunotherapy targeting the programmed cell death 1 (PD-1) receptor and its
cognate ligand PD-L1 has renewed hopes of eradicating the most difficult human cancers to …